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Abstract
Thyroid cancers are malignant tumors in the thyroid gland. DNA polymor-
phisms are playing a decisive role in unscrambling the genomic basis of tumor
formation and development in cancer. Thyroid cancer is influenced in a polygenic
and low-penetrance manner by RET gene polymorphisms and this part of the world
(North India) has not recorded any study regarding RET alterations in this very
cancer. We assessed RET G691S (rs1799939), L769L (rs1800861) and S904S
(rs1800863) polymorphisms by restriction fragment length polymorphism (RFLP)
in order to explain their potential role in the diagnosis and prognosis of Papillary
thyroid cancer (PTC) and follicular thyroid cancer (FTC). In RET G691S polymor-
phism, the total dissemination of variant alleles (GA + AA) was 62.9% in cases as
related to 44.5% in controls (P < 0.05). RET L769L variant alleles (TG + GG) was
70% in cases versus 88% in controls (P < 0.05). In RET S904S, occurrence of
variant alleles (CG + GG) was 56% in cases versus 44% in controls (P < 0.05).
G691S and L769L polymorphism advocate a “Dominant mode of inheritance”. The
S904S polymorphism approves an “Additive mode of inheritance”. In conclusion,
there was an over-representation of RET G691S/S904S polymorphisms and under-
representation of L769L polymorphism in PTC and FTC patients. Additionally, our
data suggest that some haplotypes (A T G, G T G and A T C) of RETmay act as low
penetrance alleles for predisposition of thyroid cancer.
Keywords: thyroid cancer, rearranged during transfection, RET, polymorphism,
papillary thyroid cancer, follicular thyroid cancer
1. Introduction
Cancer is a large group of diseases that vary in their age of onset, rate of growth,
state of cellular differentiation, diagnostic detectability, invasiveness, metastatic
potential, response to treatment, and prognosis. However, cancer may be a rela-
tively small number of diseases caused by similar molecular defects in cell function
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resulting from common types of alterations to a cell’s genes as per molecular and cell
biological point of view. Ultimately, abnormal gene expression causes cancer which
may occur due to mutation, translocation, amplification, deletion, loss of heterozy-
gosity, etc. Cell replication and cell death in a tumor cell population gets imbalanced
leading to an expansion of tumor tissue [1, 2].
The most common malignancy of the endocrine system is Thyroid cancer. 2% of
all diagnosed cancer cases and majority of endocrine cancer related deaths each year
are due to this cancer type [3–5].
The rearranged during transfection (RET) proto-oncogene expressed in cells of
neural crest origin and encodes a membrane tyrosine-kinase receptor [6]. However,
thyroid follicular cells may also express the RET tyrosine kinase domain [7].
Somatic RET translocations were found in some sporadic and radiation-induced
PTCs. Papillary thyroid cancer contains RET/PTC chromosomal rearrangement [8].
In this gene rearrangement, a portion of the RET gene is fused to one of several
genes. RET/PTC1 and RET/PTC3 are the most common rearrangement types in
which RET is fused to CCDC6 (also known as H4) or NCOA4 (also known as ELE1
or RFG) respectively [9, 10]. RET tyrosine kinase domain gets constitutively acti-
vated due to RET rearrangement that can lead to PTC [11, 12]. 10–20% of sporadic
PTC’s contain RET/PTC rearrangements. Patients with the history of radiation
exposure (50–80%), PTC’s from children and young adults (40–70%) have higher
frequency of RET/PTC rearrangements [13, 14].
Genetic basis of tumor formation and cancer progression is being unraveled by
DNA polymorphisms. The human genome as a whole (in which over 3.1 million
sequence variations have been mapped), represent 25–35% of the total estimated
SNPs [15]. Predisposition to several human cancers is due to polymorphisms.
Apart from RET rearrangements, the coding sequence of RET display polymor-
phisms in exon 2 (G135A, A45A), in exon 7 (G1296A, A432A), in exon 11
(G2071A, G691S), in exon 13 (T2307G, L769L), in exon 14 (C2508T, S836S), and
in exon 15 (C2712G, S904S) [16, 17]. Etiology of sporadic Hirschsprung disease
(HSCR) and MTC has been associated with RET polymorphisms [18–20]. Silent
RET polymorphisms; A45A in exon 2 and L769L in exon 13 may represent
low-penetrance risk in PTC [20]. Risk of differentiated thyroid cancer with
reference to RET Polymorphic Haplotypes was also reported by some studies [21].
The mechanisms by which the silent polymorphisms may act in the development
of cancer include transcript stability, RNA splicing, and DNA protein binding
and protein folding.
The valley of Kashmir is one of the divisions of Jammu and Kashmir State,
situated in the Himalayas. Kashmir, regarded worldwide as paradise on earth, with
over 07 million populations is heavily burdened with different organ cancers. In
Kashmir valley where incidences of almost all types of organ cancers have shown a
drastic increase in last couple of decades particularly GIT and lung cancers, the
thyroid cancer figures no less in this deadly race. Thyroid cancer is the 8th most
common cancer and 7th most common cancer among women in Kashmir valley.
The frequency of thyroid cancer has increased from 2.3% in 1995 to 5.4% in 2010 in
Kashmir valley [22]. Also, owing to the fact that there is no data on genetic alter-
ations in thyroid cancer available in our population and given the backdrop of a
significant presence of thyroid cancer patients, it is the first initiative to study the
gene alterations in Thyroid cancer patients of Kashmir Valley. In view of these
observations this study was designed to address the disease pathology associated
with the thyroid cancer through the Polymorphic analysis of RET gene SNPs—
G691S (G2071A), L769L (T2307G) and S904S (C2712G) in order to observe pattern
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of association of various SNPs G691S (G2071A), L769L (T2307G) and S904S
(C2712G) of RET gene in thyroid cancer.
2. DNA polymorphisms in thyroid cancer
The ability to visualize sequence differences directly in DNA is one of the most
important tools underlying the revolution in medical genetics. Polymorphisms are
these differences in DNA sequences when studied in the context of a population
which may be present in exons (coding regions) or introns (noncoding) regions of
genes. Family studies have been undergone by studying the genes of medical
importance through visualizing thousands of DNA polymorphisms.
Characteristically, polymorphisms denote sequence variations which confer no
deleterious effects and are present in the general population. However, as molecular
epidemiological studies were performed and the human genome project was
deciphered it became vibrant that some “polymorphisms” were not entirely harm-
less. Genes for many disorders with a clear pattern of Mendelian inheritance were
located and identified by this technique, such as, muscular dystrophies, cystic
fibrosis and neurodegenerative disorders and This technique also assists in finding
genes that predispose people to diseases in which inheritance patterns are complex,
such as diabetes, atherosclerosis, and hypertension. These polymorphisms are cru-
cial in the identification of genes important for susceptibility to common cancers,
such as colon cancer, as well as susceptibility to less common childhood tumors,
such as retinoblastoma andWilms’ tumor [23]. Over 3.1 million sequence variations
have been mapped in the human genome in which, 25–35% of the total estimated
SNPs are present [15, 24]. Individual susceptibility is likely due to genetic factors
modulating the environmental risk otherwise differentiated thyroid cancer is
described by a strong hereditability, hence, the identification of genetic variations is
important for understanding the possible mechanisms tangled in thyroid carcino-
genesis. In thyroid cancer many single nucleotide polymorphisms have been
reported in different genes and functional analysis of many single nucleotide poly-
morphisms have been carried out. It has been reported that these DNA polymor-
phisms in various genes predispose a person to higher risk of thyroid cancer and
also has a marked effect on various clinicopathological characteristics of thyroid
cancer patients [23].
3. Structure and biology of RET receptor
Located on chromosome 10q11.2 near the centromere, the RET gene includes
21 exons. RET (rearranged during transfection) was first identified by Takahashi
et al. in 1985 as a proto-oncogene that can undergo activation by cytogenic
rearrangement [25]. RET gene was cloned by the same investigators 3 years later
[26]. This gene encodes the RET receptor, a plasma membrane-bound tyrosine
kinase enzyme. RET gene is expressed by neuroendocrine and neural cells, includ-
ing parasympathetic, sympathetic and colonic ganglia, cells of the urogenital tract,
thyroid C cells, adrenal medullary cells and parathyroid cells derived from branchial
arches [27, 28]. The RET protein contains two intracellular tyrosine kinase domains,
a transmembrane domain, an extracellular region (four cadherin-like repeats, a
calcium binding site, and a cysteine-rich domain) and N terminal signal peptide.
The cysteine-rich extracellular domain is central for receptor dimerization,
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whereas, the extracellular cadherin-like domains are key for cell-cell signaling. The
RET C-terminal tail shows three splicing variants producing three protein isoforms
with 9 (RET9; short isoform), 43 (RET43; middle isoform), or 51 (RET51; long
Figure 1.
The RET protein, its functional domains, ligands and co-receptors. Left, functional domains of the three RET
isoforms. Right, canonical (unbroken lines) and noncanonical (broken lines) interactions of the RET ligands
GDNF, neurturin (NRTN), persephin (PSPN) and artemin (ARTN) with their GFRa co-receptors. Lipid
rafts are depicted as a purple box in the plasma membrane.
Figure 2.
Germline missense mutations in RET associated with MEN2 and Hirschsprung disease (HSCR). Shown are the
structure of the RET mRNA and protein. The codons mutated, the associated clinical entities, and the location of
these mutations in relation to the exons and structural domains are indicated.
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isoform) distinct amino acids at their C termini [29, 30] (Figure 1). Four ligands for
the RET receptor have been recognized so far [31, 32]. These ligands are persephin,
artemin, neurturin and the glial cell line-derived neurotrophic factor (GDNF) [33, 34].
Figure 2 summarizes various RET mutations along with disease phenotype.
4. Polymorphisms and haplotypes in RET
RET polymorphisms are might be associated with an increased relative risk for
the development of disorders derived from neural crest cells and are believed to be
genetic modifiers. High penetrant germline RET mutations have a key role in
disease development. Various disease phenotypes have relatively strong association
with RET polymorphisms. The most common RET polymorphisms; the
nonsynonymous variant in exon 11 (G691S; G2071A) and the synonymous variants
in exon 13 (L767L; T2307G), in exon 14 (S836S; C2508T) and in exon 15 (S904S;
C2712G), are being denoted as disease modifiers due to their presence in patients
with sporadic MTC and DTC [35–37]. Disease-associated germline mutations might
interact with these polymorphisms or other genetic variants, tempering the age of
onset or disease phenotype. Polymorphisms could bestow a much higher attribut-
able risk on the general population as compared with rare mutations in high-
penetrance RET gene. G691S and S904S polymorphisms of RET have a transformer
effect on the age of onset of MEN2A [38]. Sporadic MTC has been associated with
several RET polymorphisms [39]. A low-penetrance RET haplotype comprising the
wild-type allele at IVS1-126 and IVS1-1463 and a 16-basepair intron-1 deletion of
these SNPs is strongly associated with and over represented in sporadic pheochro-
mocytoma [40]. Hirschsprung disease has disease associated polymorphisms linked to
it [41, 42]. Two closely located SNPs, rs2435357 and rs2506004, in intron 1 has been
observed by two groups as disease-causing candidates on the basis of comparative
genomics, functional assays and association studies [43, 44]. G691S and S904S
linkage have been proposed previously [45]. G691S/S904S cosegregated together as
haplotype (P < 0.001) in one of the studies, proposing that these polymorphisms
are in linkage disequilibrium with each other [46].
5. RET polymorphisms and haplotypes in differentiated thyroid cancers
Follicular and parafollicular-type C cells were shown to have some inter-
connections. The MTC cells provide the microenvironment that has the capacity
to stimulate the proliferation of follicular cells, resulting in hyperplastic and
adenomatous follicles which could ultimately acquire a fully developed neoplastic
phenotype. Some patients with Hashimoto thyroiditis had C-cell hyperplasia
[47, 48]. RET receptor has been shown to express in thyroid follicular component,
which may be activated in the existence of precise ligands in the thyroid
microenvironment.
Presence of RET ligands in this microenvironment is highly reasonable because
C cells express the RET receptor. Follicular cell derived thyroid cancers contain RET
mRNA which may be activated in the presence of specific ligands [7]. So the role of
RET gene polymorphism in differentiated thyroid cancers came into existence.
Some variants within RET could represent low penetrant alleles for the PTC
phenotype. A study revealed the toughest association of A45A (G135A) and L769L
(T2307G) with PTC [20]. Borrego et al. described the seven most frequent haplo-
types in cases and controls and some of which differed in their distribution [19].
The G G C C haplotype is over-represented in both populations of sporadic PTC.
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G allele of exon 2 and the G allele of exon 13 are included in the G G C C haplotype.
A432A and S836S polymorphisms had strongest association with DTC as per the
study conducted by Lesueur et al. Yet, the scale of the detected effect between DTC
and RET SNPs was modest [20].
The mechanism by which these silent polymorphisms act and develop RET
related diseases is still a question of debate. First, stability of protein synthesis could
be disturbed by such genetic sequence variations through influence on RNA splic-
ing, hence, a new cryptic splice acceptor, donor, or enhancer site could be formed
which could result in a receptor that did not bind ligand well or in a truncated
protein [49]. RET A45A polymorphism may result in alternative splicing and pro-
duce a mRNA isoforms as per Borrego et al. [49]. They further hypothesized that
decreased protein expression on the cell surface could be due to these RNA
isoforms, erroneous ligand binding, microRNA binding, change of structure/copies
and mRNA stability synthesis of incomplete proteins and also the change in the
structure of proteins caused by slowing down of translation [50, 51]. However,
homozygosity confers the phenotypically evident changes [49]. Second, other
nearby mutations could be influenced by these silent polymorphisms. Third, the
polymorphism may incline to decreased expression of the variant allele, thus lead-
ing to low level functional haplo insufficiency. Fourth, these polymorphisms may lie
in linkage disequilibrium with other sequences that may directly confer low level
predisposition to or protection against disease. Fifth, slightly decreased efficiency of
RET translation may be due to preferential usage of tRNA molecules. The variant(s)
is less favored and the wild type would be the favored sequence. Sixth, RET gene
will be susceptible to damage by environmental insults such as radiation by these
silent polymorphisms [21]. Finally, mRNA conservation in the case of presence of
various polymorphic variants in the RET gene based on bioinformatics methods is
the answer. Codon usage bias refers to differences among organisms in the fre-
quency of occurrence of synonymous codons in mRNA. Faster translation rates and
higher accuracy is achieved by optimal codons. If the translation rate changes
before the process of beta sheet formation is finished, newly synthesized sequence
influences the structure earlier (or later) than usual and may have an effect on the
folding of the protein as the folding of the beta sheet occurs slower than the alpha
helix formation [52]. Translation or protein folding disorders because of ribosome
stalling (pause) may occur if the mutation is a change from optimal to less frequent
codon. S904S SNP gives rise to less frequent codons, so ribosome stalling can
happen. In the case of SNP L679L where the codon with higher codon usage
appears, the sheet may not finish creating the structure when the helix appears [53].
As a consequence, kinase activity and/or specificity get changed. These postulated
mechanisms are not mutually exclusive [54]. The mutant Y791F reduces the energy
of the wild type by 7% and L769L (T > G) variant the by 17%, concluding that the
L769L polymorphism reduces the MFE of small RET mRNA [45, 55]. Because of its
cosegregation of S904S with G691S, the results obtained could be interpreted as a
founder effect without influence as genetic modifier [38].
The G691S SNP occurs close to the residue Y687 in the cytoplasmic tail of the
RET amidst transmembrane region. Two scenarios are possible to explain the G691S
polymorphism exerting an effect in PTC without activation by RET rearrangement.
Firstly, although RET expressed in the parafollicular C-cells and hence might influ-
ence the microenvironment of the follicular cells [56]. Alternatively, the two amino
acids, glycine in the wild-type RET protein and serine in the polymorphic RET
variant, confer different electrochemical and conformational structures to the RET
protein, and accordingly effect the subcellular localization, folding, processing or
function of the protein [7, 57, 58]. So lot of changes in RET proto-oncogene at
mRNA level or at protein level can be conferred by single nucleotide
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polymorphisms that deregulates theMAP kinase or Akt pathway, hence
predisposing a person to thyroid cancer [18, 45].
6. Patients and controls
Blood samples of 140 cases were collected from thyroid cancer patients attend-
ing Department of Nuclear Medicine, at Sher-I-Kashmir Institute of Medical Sci-
ences (SKIMS), besides blood samples were obtained from 180 healthy controls
from the Out Patients Departments of SKIMS. The cases and controls gave written
pre-informed consent. Questionnaire was used to record demographic and clinico-
pathological characteristics of each patient. This study was approved by the Ethical
committee of the SKIMS.
0.5 ml of peripheral blood was obtained from each subject in EDTA containing
vials (200 μl of 0.5 M, pH = 8.0) and stored at 20°C till use.
7. Genotyping by restriction fragment length polymorphism
(PCR-RFLP)
Salting out method was used for the extraction of DNA from blood samples.
Automated DNA sequencing of the RAS genes revealed one frequent SNP at codon
27 (T81C SNP) of HRAS. This SNP along with three other SNPs mentioned above
were conducted in our study by PCR-RFLP which is the simple, cheap and common
genotyping method.
Restriction enzymes (REs) are called molecular scissors. They recognize and cut
specific sequences. The restriction endonuclease type II for SNP detection is selected,
such that it recognizes and cleaves one of the polymorphic bases. Upon incubation at
optimum temperature and for optimum time with a buffer, the enzyme restricts the
DNA, at a specific site. Electrophoresis of the digested products yields fragments of
sizes based on the cleavage pattern. If both the alleles harbor the base recognized by
the enzyme, fragments of sizes accounting cumulative to the undigested product are
obtained (homozygous for that base). If one of the allele harbors a different base,
then the single allele is cleaved resulting usually in 3 fragments—the original
undigested product, and two digested fragments of sizes cumulatively accounting to
the original PCR product (heterozygous). If more than one restriction site is present
within the allele, more than two fragments are made from the same allele and the
number of fragments depends on number of restriction sites present within the allele.
Absence of the base recognized by the enzyme does not result in digestion thereby
retaining the original PCR product (Homozygous).
Oligonucleotide Primers and the corresponding Restriction enzymes for codon
691, codon 769, codon 904 of RET SNPs along with Annealing temperatures are
elucidated Table 1. The PCR products were then checked on 2% agarose gel as
described earlier.
7.1 Restriction digestion procedure
10 μl of the PCR products were subjected to restriction digestion by BanI,TaqI,
and RsaI for codons 691,769 and 904 of RET SNPs respectively. The reaction
conditions were set up according to the supplier of restriction enzymes (Table 2).
For RET codon 691 the homozygous wild type (GG) has one BanI site and is
branded by 267 and 187 bp fragments while the (AA) homozygote (variant) offered
a single fragment of 454 bp and heterozygous form (G/A) showed 454, 267 and
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187 bp. For RET codon 769 the homozygous wild type (TT) has one TaqI site and is
branded by 270 and 190 bp fragments while the (GG) homozygote (variant)
offered a single fragment of 460 bp and heterozygous form (T/G) showed 460, 270
and 190 bp. In case of RET codon 904 the homozygous wild type (CC) offered a
single fragment of 332 bp and the (GG) homozygote (variant) has one RsaI site and
is branded by 224 and 108 bp fragments while as heterozygous form (C/G) showed
332, 224 and 108 bp fragments.
The PCR products were visualized on a 3% agarose gel containing 0.5 μg/ml
ethidium bromide and photographed.
8. Statistical analysis
Statistical analysis was performed by using SPSS software (V.16.0). Statistical
significance was considered when P ≤ 0.05 [59].
9. Polymorphic analysis of codon G691S, L769L and S904S of RET gene
A total of 140 cases (thyroid cancer patients) and 180 normal healthy controls
were studied for polymorphic analysis of codon G691S, L769L and S904S of RET
Amplicon Primer sequence AT
(°C)
Product
(bp)
RE* DP** (bp)
HRAS
Codon 27
(T81C)
F 50-CAGGAGACCCTGTAGGAGGA-30
R 50-GGCACCTGGACGGCGGCGCTAG-30
60 186 DraIII 128 and 58
RET
Codon 691
(G2071A)
F-5CAGAGCATACGCAGCCTGTAC-3
R-5-GCCTCGTCTGCCCAGCGTTG-3
60 454 BanI 267 and 187
Codon 769
(T2307G)
F-5-CCTGTCCACTGATCCCAAAG-3
R-5-CACTCAGCCCGTGGACTC-3
64 460 TaqI 190 and 270
Codon 904
(C2712G)
F-5-GGTCTCACCAGGCCGCTAC-3
R-5-TCGGTATCTTTCCTAGGCTTC-3
62 332 RsaI 224 and 108
*RE, restriction enzyme.
**DP, digestion product.
Table 1.
Conditions and consumables used for screening RET SNPs.
Reagents Volume
(μl)
Incubation
Water 18
Incubation temperature and time for BanI,TaqI and RsaI was 37°C for
1–16 h
10 buffer R 2
PCR product 10
Restriction
enzyme
1
Table 2.
Composition of RD mixture for codons 691, 769 and 904 of RET.
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gene. Table 3 shows the risk and demographic factors of study group.Mean age and
smoking was not having significant differences among cases and controls. The mean
age of the controls and patients were 38  14.6 years and 35  13.4 years respec-
tively. Almost 71% (100 of 140) were <45 years of age and 29% (40 of 140)
were ≥45 years of age. Only 19% (26 of 140) of the cases were females and 81% (114
of 140) were males. There was a difference between cases and controls with respect
to their gender. Only 11% (16 of 140) of thyroid cancer patients were smokers and
89% (124 of 140) were non-smokers with no significant difference between the
groups (P > 0.05). Based on the histology 84% (118 of 140) of the included cases
were papillary thyroid cancers and 16% (22 of 140) were follicular type.
9.1 Analysis of RET codon G691S, L769L and S904S polymorphism
Table 4 represents the genotype distributions of RET codon L691S, L769L and
S904S polymorphisms in the cases and controls. There was a significant difference
in the genotype distributions between cases and controls in all the three polymor-
phisms (P < 0.05) (Table 4).
In RET G691S (rs1799939), the overall dissemination of variant alleles
(GA + AA) in cases was 62.9% as compared to 44.5% in controls (P < 0.05;
OR = 2.1). Table 5 shows the Link between RET G691S phenotypes and clinico-
pathological characteristics. For further classification, our study found higher dis-
tribution of variant alleles (GA + AA) in female cases as equated to healthy
controls (63.2 vs. 47%; P < 0.05). Higher frequency of variant genotype was found
in cases with no smoking status as compare to non-smoker controls (71.4 vs. 42.9%;
P < 0.05). No significance was found between G691S polymorphism and any other
clinicopathological characteristics (Table 5).
In RET L769L (rs1800861), the overall dissemination of variant alleles
(TG + GG) in controls 88% as against 70% in cases (P < 0.05; OR = 0.3). Table 6
represents the connection between RET L769L phenotypes and clinicopathological
characteristics of patients. For further organization, our study found lower distri-
bution of variant alleles (TG + GG) in <45 years old patients as compared to healthy
controls (68 vs. 88%; P < 0.05). A significant difference was found between variant
alleles (TG + GG) of cases (males—61.5%, females—71.9%) and controls (males—
89.5%, females—87%) (P < 0.05). Non-smoker controls had higher frequency of
variant allele as compared to cases with no smoking status (87 vs. 67.7%; P < 0.05).
A higher frequency of variant alleles (82.1%) (62%) was found in thyroid cancer
patients having no history of benign thyroid disease as compared to patients with
history of benign thyroid disease (62%; P < 0.05). RET gene L769L polymorphism
was not found to be associated with any other clinicopathological characteristics
(Table 6).
In RET S904S (rs1800863), the overall dissemination of variant alleles
(CG + GG) in controls was 44% as against 56% in cases (P < 0.05; OR = 1.6).
Table 7 lists the connection between RET S904S phenotypes and clinicopathologi-
cal characteristics of study cases and controls. For further arrangement, our study
found lower distribution of variant alleles (CG + GG) in controls of ≥45 years of age
as compared to matched thyroid cancer cases (28 vs. 45%; P < 0.05). We found a
higher distribution of variant alleles (CG + GG) in male thyroid cancer patients as
compared to healthy controls (69 vs. 57%; P < 0.05). A lower frequency of variant
alleles was found in thyroid cancer patients having no history of benign thyroid
disease when compared to patients having benign thyroid disease (43 vs. 63%;
P < 0.05). No association was found between any other clinicopathological
characteristic and RET gene L769L polymorphism (Table 7).
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Characteristics Cases
n = 140 (%)
Controls
n = 180 (%)
χ
2-value P value
Age group
<45 100 (71) 130 (72) 0.025 >0.05
≥45 40 (29) 50 (28)
Sex
Female 114 (81) 104 (58) 20.2 <0.05
Male 26 (19) 76 (42)
Dwelling
Rural 112 (80) 98 (54.4) 22.8 <0.05
Urban 28 (20) 82 (45.6)
Smoking
Never 124 (89) 140 (77.8) 6.3 <0.05
Ever 16 (11) 40 (22.2)
Benign thyroid disease
Yes 84 (60)
No 56 (40)
TSH levels
Elevated 100 (71)
Normal 40 (29)
Histological types
Papillary 118 (84)
Follicular 22 (16)
Tumor grade
WD 134 (96)
PD 06 (04)
Stage, <45 years
Stage I 94(67)
Stage II 06 (4.3)
Stage, ≥45 years
Stage I and II 36 (25.7)
Stage III and above 04 (03)
Vascular/capsular invasion
Yes 68 (48.5)
No 72 (51.5)
Lymph node metastasis
Yes 52 (37)
No 88 (63)
TSH, thyroid stimulating hormone; WD, well differentiated thyroid cancer; PD, poorly differentiated thyroid cancer.
Table 3.
Details of thyroid cancer cases and controls for the study.
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9.2 Mode of inheritance in genetic association studies of RET polymorphisms
The risk of thyroid cancer with respect to gender and smoking status with RET
G691S (G2071A), L769L (T2307G) and S904S (C2712G) polymorphisms. Recessive,
dominant, co-dominant and additive inheritance models were used to assess
Adjusted ORs. The inheritance model matching individual SNP data shall have
lowest P-value. For RET G691S and L769L polymorphism dominant inheritance
model is appropriate while as additive inheritance model is appropriate for RET
S904S polymorphism. The results are presented in Tables 8–10.
9.3 Association between RET haplotypes and thyroid cancer risk
In order to evaluate the combined effect of the three polymorphisms on thyroid
cancer risk Haplotype analyses were conducted. Among both cases and controls all
haplotypes have frequencies >5%. G2071/2307G/ C2712 (GGC) was the most
SNP Cases
n = 140 (%)
Controls
n =180 (%)
OR (95% CI) P-value
G691S (G2071A)
Genotype
GG 52 (37.1) 100 (55.5) 1.0 (ref.)
GA 64 (45.7) 64 (35.5) 1.9 (1.1–3.2) <0.05
AA 24 (17.2) 16 (09) 2.9 (1.2–6.6)
Allele type
G 168(60) 264 (73.3) 1.0 (ref.)
A 112(40) 96 (26.7) 1.8 (1.2–2.5) <0.05
L769L (T2307G)
Genotype
TT 42 (30) 22 (12) 1.0 (ref.)
TG 70 (50) 110 (61) 0.32 (0.17–0.57) <0.05
GG 28 (20) 48 (27) 0.30 (0.15–0.6)
Allele type
T 154(55) 154 (42) 1.0 (ref.)
G 126(45) 206 (58) 0.61 (0.44–0.82) <0.05
S904S (C2712G)
Genotype
CC 62 (44) 102 (56) 1.0 (ref.)
CG 64 (46) 70(40) 1.5 (0.93–2.4) <0.05
GG 14 (10) 08 (04) 2.8 (1.1–7.0)
Allele type
C 188(67) 274 (76) 1.0 (ref.)
G 92(33) 86 (24) 1.5 (1.0–2.1) <0.05
TSH, thyroid stimulating hormone; WD, well differentiated thyroid cancer; PD, poorly differentiated thyroid cancer;
BTD, benign thyroid disease.
Table 4.
Genotype frequencies of cases and controls in RET polymorphisms.
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Cases
n (%)
GG
n (%)
GA + AA
n (%)
Controls
n (%)
GG
n (%)
GA + AA
n (%)
OR (95% CI) P value
Overall
genotype
n = 140 52 (37.1) 88 (62.9) n = 180 100 (55.5) 80 (44.5) 2.1 (1.3–3.2) <0.05
Age group
<45 100 (71) 30 (30) 70 (70) 130 (72) 62 (48) 68 (52) 2.1 (1.2–3.6) <0.05
≥45 40 (29) 22 (55) 18 (45) 50 (28) 38 (76) 12 (24) 2.6 (3.6–6.2) <0.05
Sex
Female 114 (81) 42 (36.8) 72 (63.2) 104 (58) 60 (58) 44 (42) 2.3 (1.3–3.9) <0.05
Male 26 (19) 10 (38.5) 16 (61.5) 76 (42) 40 (53) 36 (47) 1.8 (0.72–4.4) >0.05
Dwelling
Rural 112 (80) 44 (39.3) 68 (60.7) 98 (54.4) 56 (57.1) 42 (42.9) 2.0 (1.2–3.4) <0.05
Urban 28 (20) 08 (28.5) 20 (71.5) 82 (45.6) 44 (53.6) 38 (46.4) 2.9 (1.1–7.2) <0.05
Smoking
Never 124 (89) 42 (28.6) 82 (71.4) 140
(77.8)
80 (57.1) 60 (42.9) 2.6 (1.5–4.5) <0.05
Ever 16 (11) 10 (62.5) 06 (37.5) 40 (22.2) 20 (50) 20 (50) 0.6 (0.1–2.8) >0.05
BTD
Yes 84 (60) 30 (35.7) 54 (64.2)
No 56 (40) 22 (39.2) 34 (60.8) 1.2 (0.8–1.9) >0.05
TSH levels
Elevated 100 (71) 40 (40) 60 (60)
Normal 40 (29) 12 (30) 28 (70) 0.6 (0.2–1.5) >0.05
Histological
types
Papillary 118(84) 44(37.2) 74(62.8)
Follicular 22(16) 08(36.3) 14(63.7) 1.0 (0.3–3.2) >0.05
Tumor
grade
WD 134 (96) 50 (37.3) 84 (62.7)
PD 06 (04) 02 (33.3) 04 (66.7) 0.8 (0.06–9.7) >0.05
Stage, <45
years
Stage I 94 (67) 28 (29.7) 66 (70.3)
Stage II 06 (4.3) 02 (33.3) 04 (66.7) 1.2 (0.1–15.3) >0.05
Stage, ≥45
years
Stage I and
II
36 (25.7) 20 (55.5) 16 (44.5)
Stage III
and above
04 (03) 02 (50) 02 (50) 0.8 (0.09–6.3) >0.05
Vascular/
capsular
invasion
Yes 68 (48.5) 22 (32.3) 46 (67.7)
No 72 (51.5) 30 (41.6) 42 (58.4) 1.5 (0.75–3) >0.05
Lymph node
metastasis
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Cases
n (%)
GG
n (%)
GA + AA
n (%)
Controls
n (%)
GG
n (%)
GA + AA
n (%)
OR (95% CI) P value
Yes 52 (37) 18 (34.6) 34 (65.4)
No 88 (63) 34 (38.6) 54 (61.4) 1.2 (0.5–2.7) >0.05
TSH, thyroid stimulating hormone; WD, well differentiated thyroid cancer; PD, poorly differentiated thyroid cancer; BTD, benign
thyroid disease.
Table 5.
Clinicopathological characteristics vs. RET G691S (G2071A) genotypes.
Cases
n (%)
TT
n (%)
TG + GG
n (%)
Controls
n (%)
TT
n (%)
TG + GG
n (%)
OR (95% CI) P value
Overall
genotype
n = 140 42 (30) 98 (70) n = 180 22
(12)
158 (88) 0.3 (0.17–0.6) <0.05
Age group
<45 100 (71) 32 (32) 68 (68) 130 (72) 16
(12)
114 (88) 0.3 (0.14–0.5) <0.05
≥45 40 (29) 10 (25) 30 (75) 50 (28) 06
(12)
44 (88) 0.4 (0.13–1.2) >0.05
Sex
Female 114 (81) 32 (28.0) 82 (71.9) 104 (58) 14
(13)
90 (87) 0.4 (0.18–0.85) <0.05
Male 26 (19) 10 (38.4) 16 (61.5) 76 (42) 08
(10.5)
68 (89.5) 0.2 (0.07–0.6) <0.05
Dwelling
Rural 112 (80) 36 (32.1) 76 (67.8) 98 (54) 10
(10)
88 (90) 0.23 (0.1–0.5) <0.05
Urban 28 (20) 06 (21.4) 22 (78.5) 82 (46) 12
(15)
70(85) 0.6 (0.2–1.8) >0.05
Smoking
Never 124 (89) 40 (32.2) 84 (67.7) 140 (78) 18
(13)
122 (87) 0.3 (0.16–0.55) <0.05
Ever 16 (11) 02 (12.5) 14 (87.5) 40 (22) 04
(10)
36 (90) 1.1 (0.16–6.2) >0.05
BTD
Yes 84 (60) 32 (38) 52 (62) 0.35(0.15–0.78) <0.05
No 56 (40) 10 (17.8) 46 (82.1)
TSH levels
Elevated 100 (71) 30 (30) 70 (70) 0.25(0.1–0.62) >0.05
Normal 40 (29) 12 (30) 28 (70)
Histological
types
Papillary 118 (84) 36 (30.5) 82 (69.4) 0.85 (0.3–2.2) >0.05
Follicular 22 (16) 06 (27.2) 16 (72.7)
Tumor grade
WD 134 (96) 40 (29.8) 94 (70.14) 1.17 (0.19–6.5) >0.05
PD 06 (04) 02 (33.3) 04 (66.6)
Stage, <45 years
Stage I 94 (67) 28 (29.8) 66 (70.2) 4.7 (0.8–26.8) >0.05
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Cases
n (%)
TT
n (%)
TG + GG
n (%)
Controls
n (%)
TT
n (%)
TG + GG
n (%)
OR (95% CI) P value
Stage II 06 (4.3) 04 (66.6) 02 (33.3)
Stage, ≥45 years
Stage I and II 36 (25.7) 08 (22.2) 28 (77.8) 3.5 (0.42–28.7) >0.05
Stage III and
above
04 (03) 02 (50) 02 (50)
Vascular/
capsular
invasion
Yes 68 (48.5) 22 (32.3) 46 (67.7) 0.8 (0.4–1.6) >0.05
No 72 (51.5) 20 (27.8) 52 (72.2)
Lymph node
metastasis
Yes 52 (37) 18 (34.6) 34 (65.4) 0.7 (0.32–1.4) >0.05
No 88 (63) 24 (27.2) 64 (72.8)
TSH, thyroid stimulating hormone; WD, well differentiated thyroid cancer; PD, poorly differentiated thyroid cancer; BTD, benign
thyroid disease.
Table 6.
Clinicopathological characteristics vs. RET L769L (T2307G) genotypes.
Cases
n (%)
CC
n (%)
CG + GG
n (%)
Controls
n (%)
CC
n (%)
CG + GG
n (%)
OR (95% CI) P-value
Overall
genotype
n = 140 62 (44) 78 (56) n = 180 102 (56) 78 (44) 1.6 (1.0–2.4) <0.05
Age group
<45 100 (71) 40 (64.5) 60 (35.5) 130 (72) 66 (51) 64 (49) 1.5 (0.9–2.9) >0.05
≥45 40 (29) 22 (55) 18 (45) 50 (28) 36 (72) 14 (28) 2.1 (0.84–5.0) <0.05
Sex
Female 114 (81) 54 (47) 60 (53) 104 (58) 58 (56) 46 (44) 1.4 (0.8–2.4) >0.05
Male 26 (19) 08 (31) 18 (69) 76 (42) 44 (43) 32 (57) 3.1 (1.2–8.0) <0.05
Dwelling
Rural 112 (80) 46 (41) 66(59) 98 (54) 54 (55) 44 (45) 1.7 (0.96–2.9) >0.05
Urban 28 (20) 16 (57) 12(43) 82 (46) 48 (58.5) 34 (41.5) 1.05 (0.4–2.4) >0.05
Smoking
Never 124 (89) 56 (45) 68 (55) 140 (78) 78 (56) 62 (44) 1.5 (0.9–2.4) >0.05
Ever 16 (11) 06 (37.5) 10 (62.5) 40 (22) 24 (60) 16 (40) 2.5 (0.75–8.2) >0.05
BTD
Yes 84 (60) 30 (36) 54 (64)
No 56 (40) 32 (57) 24 (43) 2.4 (1.2–4.8) <0.05
TSH levels
Elevated 100 (71) 40 (40) 60 (60)
Normal 40 (29) 22 (55) 18 (45) 1.8 (0.7–3.7) >0.05
Histological
types
Papillary 118 (84) 56 (47) 62 (53)
14
Knowledges on Thyroid Cancer
Cases
n (%)
CC
n (%)
CG + GG
n (%)
Controls
n (%)
CC
n (%)
CG + GG
n (%)
OR (95% CI) P-value
Follicular 22 (16) 06 (27) 16 (73) 0.4 (0.15–
1.08)
>0.05
Tumor grade
WD 134 (96) 60 (45) 74 (55)
PD 06 (04) 02 (33) 04 (67) 0.6 (0.10–3.4) >0.05
Stage, <
45 years
Stage I 94 (67) 40 (42.5) 54 (57.5)
Stage II 06 (4.3) 02 (33) 04 (67) 0.7 (0.12–4.0) >0.05
Stage, ≥45 years
Stage I and II 36 (25.7) 18 (50) 18 (50)
Stage III and
above
04 (03) 02 (50) 02 (50) 1.0 (0.12–7.9) >0.05
Vascular/
capsular
invasion
Yes 68 (48.5) 32 (47) 36 (53)
No 72 (51.5) 30 (41.7) 42 (58.3) 0.8 (0.4–1.56) >0.05
Lymph node
metastasis
Yes 52 (37) 28 (54) 24 (46)
No 88 (63) 34 (39) 54 (61) 0.5 (0.25–1.0) >0.05
TSH, thyroid stimulating hormone; WD, well differentiated thyroid cancer; PD, poorly differentiated thyroid cancer; BTD, benign
thyroid disease.
Table 7.
Clinicopathological characteristics vs. RET S904S (C2712G) genotypes.
Genotypes and alleles (patients vs.
controls)
Cases
(n = 140)
Controls
(n = 180)
OR (95% CI) P value
Recessive model (AA vs. GA + GG)
GA + GG 116 164 1.0 (ref.)
AA 24 16 2.12 (1.0–4.7) 0.027
Dominant model (AA+ GA vs. GG)
GG 52 100 1.0 (ref.)
AA + GA 88 80 2.11 (1.3–3.3) 0.001
Co-dominant model (GA vs. AA + GG)
AA + GG 76 116 1.0 (ref.)
GA 64 64 1.5 (1.0–2.3) 0.066
Additive model (AA vs. GG)
GG 52 100 1.0 (ref.)
AA 24 16 2.8 (1.4–5.7) 0.003
Table 8.
G691S (G2071A) polymorphism association with thyroid cancer.
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common haplotype, with frequencies of 24% in cases and 33% in controls. The
complete dissemination of various haplotypes between cases and controls presented
a clear difference (P < 0.0001). Haplotype pattern for the three SNPs is shown in
Table 11. Haplotypes with frequency <1% was omitted from the study. After
stratified by gender, age and smoking status the haplotype frequencies were esti-
mated from the genotyping data. In our study, the most common haplotype is taken
Genotypes and alleles (patients vs.
controls)
Cases
(n = 140)
Controls
(n = 180)
OR (95% CI) P value
Recessive model (GG vs. TG + TT)
TG + TT 112 132 1.0 (ref.)
GG 28 48 0.7 (0.4–1.2) 0.17
Dominant model (GG + TG vs. TT)
TT 42 22 1.0 (ref.)
GG + TG 98 158 0.32 (0.2–0.6) 0.000
Co-dominant model (TG vs. GG + TT)
GG + TT 70 70 1.0 (ref.)
TG 70 110 0.63 (0.4–1.0) 0.047
Additive model (GG vs. TT)
TT 42 22 1.0 (ref.)
GG 28 48 0.3 (0.15–0.6) 0.001
Table 9.
Genetic model for L769L (T2307G) polymorphism.
Genotypes and alleles (patients vs.
controls)
Cases
(n = 140)
Controls
(n = 180)
OR (95% CI) P-value
Recessive model (GG vs. CG + CC)
CG + CC 126 172 1.0 (ref.)
GG 14 08 2.4 (0.97–5.8) 0.051
Dominant model (GG + CG vs. CC)
CC 62 102 1.0 (ref.)
GG + CG 78 78 1.64 (1.0–2.6) 0.028
Co-dominant model (CG vs. GG + CC)
GG + CC 76 110 1.0 (ref.)
CG 64 70 1.3 (0.8–2.0) 0.22
Additive model (GG vs. CC)
CC 62 102 1.0 (ref.)
GG 14 08 2.8 (1.1–7.2) 0.021
Table 10.
Genetic model for S904S (C2712G) polymorphism.
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as the reference group and haplotype-specific ORs are estimated by the haplotype-
based logistic regression method [60]. The frequencies for the estimated 3-marker
haplotypes among patients and controls are shown in Table 11.
10. Conclusion
Thyroid tumors signify a proper model for the study of epithelial neoplastic
transformation. At the genomic level, thyroid cancers gather a number of changes
and it has been projected that genomic instability has a vital role in the development
of thyroid neoplasms [61].
With erudite genetic tools producing a treasure of information, we have added
improved vision into the mechanisms driving thyroid tumor development. Recog-
nition of these features is crucial to the management of patients with TC. New
therapeutics is being designed based on our improved understanding of this disease
course.
In Kashmiri population we studied genetic alterations of RET genes in thyroid
cancer patients. Following are the major findings of our study;
• In RET G691S (rs1799939), the total distribution of variant alleles (CA + AA) in
controls was 44.5% as against 62.9% in controls which revealed a 2-fold higher
risk of variant allele (TC + CC) in cases against the controls (P < 0.05).
• In RET L769L (rs1800861), the total distribution of variant alleles (TG + GG)
in controls was 88% as against 70% in cases (P < 0.05; OR = 0.3).
• In RET S904S (rs1800863), the total distribution of variant alleles (CG + GG)
in controls was 44% as against 56% in cases (P < 0.05; OR = 1.6).
• We found higher distribution of variant alleles (CG + GG) in TC cases of
≥45 years of age and male gender (45 and 69%) as compared to matched
healthy controls (28 and 57%) (P < 0.05). Association was also observed with
BTD (P < 0.05).
• RET G691S and L769L polymorphisms follow “Dominant inheritance model”
while as “Additive inheritance model” is appropriate for analysis of RET S904S
polymorphism.
G2071A T2307G C2712G Total
frequency
Cases Controls Cumulative
frequency
OR (95% CI) P value
G G C 0.3061 0.2498 0.3337 0.3061 1.00 (ref) –
G T C 0.2122 0.2004 0.2321 0.5183 0.94 (0.48–1.84) 0.86
A G C 0.1224 0.1084 0.1503 0.6407 1.26 (0.55–2.87) 0.59
A T G 0.0999 0.1442 0.0657 0.7406 0.24 (0.10–0.57) 0.0012
A T C 0.0843 0.1129 0.0506 0.8249 0.38 (0.17–0.83) 0.016
G T G 0.0817 0.0925 0.0738 0.9066 0.23 (0.08–0.64) 0.0051
G G G 0.075 0.0573 0.0938 0.9816 1.59 (0.59–4.31) 0.36
A G G 0.0184 0.0345 0 1 0.05 (0.00–1.37) 0.076
The OR (95% CI) of thyroid cancer associated with each haplotype was estimated by comparison with the common reference haplotype.
ref: reference.
Table 11.
Haplotype frequencies and its association with thyroid cancer.
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• In RET codon G691S, L769L and S904S polymorphism the most over-
represented haplotype is A T G followed by G T G and A T C depending upon
their Akaike information criteria (P-value).
In conclusion, our study shows that among different polymorphisms
predisposing to thyroid tumors, RET gene polymorphism is among the prominent
ones. Our results support the earlier reports of the G691S/S904S polymorphism in
RET gene as a marked predisposing factor for the risk of developing thyroid tumors
in our population with G691S variant showing an increased risk for the non-
smokers but this needs to be authenticated in a large sample study in the future to
determine the course of thyroid cancer. Further we conclude L769L polymorphism
to be protective in our series of thyroid cancer patients. Apart from it our data
suggest that some specific haplotypes (A T G, G T G, and A T C) of RET are over-
represented and may act as low penetrance alleles in the predisposition to
thyroid cancer.
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